Lamellar Biomedical Eyes Sales And Pipeline Growth With New Cash
Scottish biotech Lamellar Biomedical has raised new cash to support commercialization of its pipeline of biomimetic products. The company's proprietary Lamellasome technology creates mimetics that replicate the actions of lamellar bodies to target diseases and conditions associated with thick sticky mucosal surfaces.
You may also be interested in...
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.